Temozolomide for aggressive pituitary tumors in Latin America
Part of Brain & nervous system, Cancer, Hormones & metabolism clinical trials.
This study looks back at medical records of people in Latin America who have an aggressive pituitary tumor or pituitary cancer and were treated with the chemotherapy drug temozolomide. The goal is to see how well the treatment worked by comparing scans taken before and after therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed aggressive pituitary tumor (one that has grown quickly, spread, or not responded to other treatments) or pituitary carcinoma (a cancerous pituitary tumor that has spread).
- You have already been treated with the chemotherapy drug temozolomide for this condition.
- You have imaging scans (like MRI) from before and after your temozolomide treatment, so the doctors can measure how the tumor responded.
- You started temozolomide within the study period being looked at.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding temozolomide chemotherapy after radiation helps control a type of low-grade brain tumor that was not fully removed. It may help reduce the chance the tumor comes back, compared with standard post-radiation care.
This trial studies a new form of the chemotherapy drug temozolomide (called Amitzo) in people with aggressive brain tumors (grade III or IV gliomas). It aims to see if the drug is safe and effective, and is for patients who need treatment for a new diagnosis or for tumors that have come back after standard care.
This trial tests a new combination of two drugs (tarlatamab and temozolomide) for people with certain types of aggressive brain or central nervous system tumors that have come back or not responded to standard treatment. The hope is that this combination may work better against tumors that have a specific marker called DLL3.
This trial tests an experimental drug called NLG802 combined with the chemotherapy drug temozolomide for children and young adults whose brain or spinal cancer has come back or has not responded to treatment. The goal is to see if this combination can help shrink tumors or slow their growth.
This Phase 2 study tests a gentler, steady schedule of temozolomide in people with advanced low-grade neuroendocrine neoplasms who are “unfit” for stronger treatments. The goal is to shrink or control the cancer while being safer for people with weaker health or organ function.
This study tests whether Tumor Treating Fields (a wearable electrical device placed on the scalp) combined with temozolomide can treat brainstem gliomas (tumors in key parts of the brainstem). It may help slow tumor growth and improve outcomes for adults who have already finished surgery/radiation or are otherwise ready for the next treatment step.
Hear when a new Pituitary Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.